The managing partners of CLS are Mr. A. Barr Dolan, Dr. Donald C. Harrison, Mr. Fred M. Schwarzer and Dr. Nelson Teng. Collectively, they have more than 70 years of experience creating and nurturing early stage life sciences companies, and they have worked together for over 15 years to build successful life sciences companies. The managing partners bring together a unique combination of medical, scientific, operational, venture capital, financial and legal experience. Two of the managing partners, Dr. Harrison and Dr. Teng, bring a level of experience and clinical and scientific knowledge in cardiology and cancer that is matched by few venture capital general partners. Mr. Dolan was one of the pioneer life sciences venture capital investors, and he brings twenty years of active life sciences investing experience to the Fund. Mr. Schwarzer brings extensive operational, business development, finance and legal skills to the Fund. The investment professionals at CLS have complementary skills which are well matched to our portfolio companies’ stage of investment and investment strategy, and the skill sets of the CLS team are particularly valuable to our portfolio companies as they progress through product development and clinical trials to liquidity.
A. Barr Dolan
Barr has extensive venture capital investment experience and extensive experience as a founder of life sciences companies. Prior to the founding of CLS, Barr was a founding partner of the Charter Ventures family of venture capital funds. Barr has been an active founder of multiple life sciences companies, including the women’s health company Adeza Biomedical (ADZA), cardiac catheter company EP Technologies (IPO, then acquired by Boston Scientific), biotech company Heska Corporation (HSKA), biotech company Univax Biologics (IPO, then acquired by NABI) and women’s health medical device company Vesta (acquired by Pfizer). Among his many roles with these companies, Barr has also served as interim chief executive officer of Adeza and EP Technologies. Barr has made venture capital investments in more than 50 life sciences companies, including specialty pharma company Intermune (ITMN), drug delivery company Advanced Polymer Systems (APPA), biotech company Calgene (IPO, then acquired by Monsanto), biotech company EOS Biotechnology (acquired by Protein Design Labs), biotech company Genelabs Technologies (GNLB), biotech company Geron (GERN), biotech company Valentis (VLTS), medical device company Orquest (acquired by Johnson & Johnson), drug delivery company Penederm (acquired by Mylan Laboratories) and biotech company Tularik (TLRK). Barr holds a BA in chemistry and an MS in engineering from Cornell University, an MA in applied science from Harvard University and an MBA from Stanford University.
Donald C. Harrison, M.D.
Don has extensive clinical and scientific expertise with respect to cardiology, extensive medical practice management experience and he has been the founder and director of numerous life sciences companies. Immediately prior to the founding of CLS, Don was the senior vice president and provost for health affairs at the University of Cincinnati Medical Center, where he was responsible for three hospitals, more than 1000 faculty and over $240 million in funded research. Previously, he was chief of cardiology at Stanford University and co-director of the Falk Cardiovascular Research Center at Stanford University. Among his many professional honors, he has been the president of the American Heart Association and a trustee of the American College of Cardiology. He has also been a member of the editorial boards of 13 professional journals, including the American Journal of Cardiology, Drugs, Drug Delivery, In Pharma, British Journal of Clinical Practice, Chest, Heart and Lung, Practical Cardiology, Clinical Cardiology, Journal of Cardiovascular Pharmacology and Cardiovascular Drugs and Therapy. He is also an author of seven books and more than 585 scientific articles and reviews. In addition to Don’s professional accomplishments, he has been the chairman of the Advisory Science Board for Hewlett Packard, a member of the Strategic Advisory Panel of Boston Scientific, a member of the Worldwide Science Advisory Board of Bristol Myers and chairman of the Cardiology Advisory Panel of Procter and Gamble. Don has also received the Award for Entrepreneurial Excellence by the University of Cincinnati’s Center for Entrepreneurship Education and Research. Don has been very active as an entrepreneur over the last twenty years. He was a founder with Barr of cardiac catheter company EP Technologies (IPO, then acquired by Boston Scientific), a founder with Barr and Nelson of women’s health company Vesta (acquired by Pfizer), a founder of atrial fibrillation medical device company AtriCure (ATRC) and a founder of the University of Cincinnati life sciences incubator BIO/START. In addition to his CLS board seats, Don is also a board member of the international clinical regulatory organization Kendle International. He was also a board member of the successful medical device company SciMed (acquired by Boston Scientific). Don holds an MD from the University of Alabama, School of Medicine and a BA in chemistry from Birmingham Southern College. He also received an honorary Doctor of Law from Birmingham Southern College.
Fred M. Schwarzer
Fred has extensive operational and fundraising experience, including the development of corporate partnerships and the structuring of venture capital investments and acquisitions. Prior to founding CLS, Fred was the chief executive officer and then chairman of Heska (HSKA). During his tenure at Heska, Fred completed corporate partnerships with Bayer and Novartis, completed seven acquisitions and Heska’s initial public offering and follow-on public offering. During this time, Heska also obtained its first FDA approval, launched its first products, created its sales and marketing effort and grew its revenue to approximately $40 million. Fred has also been the president and chief executive officer of Mingly Capital Corporation, which was focused on developing cross-border opportunities in life sciences and information technology. He was also executive director of the Mingly Corporation Limited (listed on the Hong Kong Stock Exchange) and prior to that he was a senior vice president of C.M. Capital, a diversified asset management company. Fred began his professional career as an attorney representing technology companies and venture capitalists. In 1985, he was made a partner with Pillsbury, Madison & Sutro (now Pillsbury, Winthrop) and in 1988 he founded the firm of General Counsel Associates (now GCA Law Partners). Fred holds a JD from the University of California, Berkeley, Boalt Hall School of Law and a BA from the University of Michigan.
Nelson Teng, M.D.
Nelson has extensive scientific and medical insight with respect to cancer, women’s health, surgery and monoclonal antibodies. He also has a vast network of relationships with leading scientists and physicians throughout the world and has been the founder and director of multiple biotechnology companies. Since 1986, Nelson has been chief of gynecologic oncology at Stanford University’s School of Medicine. Nelson is a named inventor on fifteen patents and is an author of more than 100 publications. Over the past 20 years, the scientific research at Nelson’s laboratory at Stanford University has focused on cancer biology and gynecologic diseases. His laboratory has created numerous monoclonal antibodies of clinical interest, including the first human therapeutic monoclonal antibody to be taken into clinical trials. Nelson has also been a principal investigator for more than 30 cancer clinical trials. Among his many professional honors, Nelson has been honorary senior registrar at Hammersmith Hospital (London), Royal Postgraduate College and research scientist at the Massachusetts Institute of Technology. He is a fellow of the American College of Surgeons and the American College of Obstetricians and Gynecologists, former president of the Western Association of Gynecologic Oncologists and former chairman of the uterine and cervical cancer committee and member of both the ovarian cancer committee and the cervical cancer screening committee of the National Comprehensive Cancer Network. Nelson has also served on various committees within the Gynecologic Oncology Group, a national clinical trial consortium sponsored by the National Cancer Institute. Nelson is board certified in gynecology, gynecologic oncology and obstetrics. In addition to his many academic and clinical accomplishments, Nelson has also been an active entrepreneur over the past twenty years. He was a founder of several companies with Barr, including women’s health care company Adeza Biomedical (ADZA), biotech company Univax Biologics (IPO, then acquired by NABI) and women’s health care company Vesta (acquired by Pfizer). He has also served as vice president of research at Adeza Biomedical. Nelson also has extensive experience in Asia and, with respect to biotechnology matters, has been an advisor to Asian governments and Asian-based venture capital funds such as Vertex and Mingly Capital. Nelson received a PhD in biophysics from the University of California, Berkeley, an MD from the University of Miami and is a graduate of the postgraduate program at the Stanford University Graduate Business School.
Gino Di Sciullo, Ph.D.
Gino joined CLS in 2006 and has more than 10 years of experience in venture investing, product development, business development and intellectual property management. Gino is currently serving as the CEO of Great Lakes Pharmaceutical, a CLS portfolio company. Gino began his biotech career in a start-up environment working for Cytologix (acquired by DAKO), an early stage diagnostic device company in Boston. In 2001, he joined RCT, an intellectual property licensing and technology investment firm, where he was responsible for business and scientific due diligence and project development management of RCT portfolio companies. At RCT, he also served as the CEO of APT Pharmaceuticals and the manager of Alimmune, a joint venture between RCT and Abgenix (now Amgen). Gino holds a PhD in immunology and an MS in medical science from the Boston University School of Medicine and a BS in biology from Stonehill College.
Andrew K. Klatt
Partner, Chief Financial Officer
Andy has served as chief financial officer for CLS since its inception and has been chief financial officer of the Charter Ventures family of funds since 1998. Previously, Andy spent 13 years as chief financial officer for the Mayfield funds, where he was responsible for the financial and administrative management of more than 20 venture capital partnerships with a total committed capital of more than $700 million. In addition to his venture capital experience, Andy has served as the interim chief financial officer for several early stage venture backed companies. Andy is a certified public accountant. He previously served as a divisional controller with Intel and as an audit staff member with Arthur Anderson & Co. Andy holds a BS in accounting and finance from the University of California, Berkeley.
Jean has been with CLS since its inception. She reviews and evaluates prospective drug development, medical device and healthcare information technology investment opportunities and monitors and reports on the firm’s existing portfolio investments. Prior to joining CLS, Jean was an analyst with Mingly Capital, where she assisted with analyzing potential life sciences and information technology investment opportunities. Prior to joining Mingly, she worked as an acting deputy city attorney in the Mountain View City Attorney’s Office. Jean holds a JD and BS magna cum laude from Indiana University, Bloomington.